Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Free Cash Flow (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Free Cash Flow for 8 consecutive years, with -$29.6 million as the latest value for Q4 2024.

  • Quarterly Free Cash Flow fell 41.68% to -$29.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$100.0 million through Dec 2024, down 6.11% year-over-year, with the annual reading at -$156.3 million for FY2025, 56.32% down from the prior year.
  • Free Cash Flow hit -$29.6 million in Q4 2024 for Solid Biosciences, down from -$23.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $1.2 million in Q4 2020 to a low of -$32.8 million in Q4 2022.
  • Historically, Free Cash Flow has averaged -$21.4 million across 5 years, with a median of -$21.3 million in 2021.
  • Biggest five-year swings in Free Cash Flow: surged 105.7% in 2020 and later tumbled 1732.48% in 2021.
  • Year by year, Free Cash Flow stood at $1.2 million in 2020, then crashed by 1732.48% to -$20.4 million in 2021, then crashed by 61.36% to -$32.8 million in 2022, then soared by 36.38% to -$20.9 million in 2023, then tumbled by 41.68% to -$29.6 million in 2024.
  • Business Quant data shows Free Cash Flow for SLDB at -$29.6 million in Q4 2024, -$23.7 million in Q3 2024, and -$21.5 million in Q2 2024.